Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspire-Lakewood HoldingsASBP +2.42%11 Return-on-Tangible-Equity is -64.92% as of Jun. 2026. GuruFocus rates ASBP with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Aspire-Lakewood Holdings ranks worse than 83402.75% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Aspire-Lakewood Holdings's annualized net income for the quarter that ended in Jun. 2026 was $-5.07 Mil. Aspire-Lakewood Holdings's average shareholder tangible equity for the quarter that ended in Jun. 2026 was $7.81 Mil. Therefore, Aspire-Lakewood Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was -64.92%.
The historical rank and industry rank for Aspire-Lakewood Holdings's Return-on-Tangible-Equity or its related term are showing as below:
ASBP's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -41.28 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Aspire-Lakewood Holdings Return-on-Tangible-Equity Related Terms
Aspire-Lakewood Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Aspire-Lakewood Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASBP vs PDSB, KPRX, SNTI: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Aspire-Lakewood Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspire-Lakewood Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aspire-Lakewood Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Aspire-Lakewood Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -64.92% mean?
Aspire-Lakewood Holdings (ASBP) has a Return-on-Tangible-Equity of -64.92% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aspire-Lakewood Holdings and its competitors. According to the industry distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 1199 companies in the Biotechnology industry.
Is Aspire-Lakewood Holdings' Return-on-Tangible-Equity too high?
Aspire-Lakewood Holdings' current Return-on-Tangible-Equity is -64.92%. Based on the distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aspire-Lakewood Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Aspire-Lakewood Holdings' Return-on-Tangible-Equity compare to PDSB and KPRX?
According to the Biotechnology industry distribution chart, Aspire-Lakewood Holdings ranks #999999 out of 1199 companies for Return-on-Tangible-Equity. This places Aspire-Lakewood Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aspire-Lakewood Holdings and its competitors. Aspire-Lakewood Holdings's current Return-on-Tangible-Equity is -64.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire-Lakewood Holdings stock overvalued right now?
Aspire-Lakewood Holdings (ASBP) has a current Return-on-Tangible-Equity of -64.92%. The current Return-on-Tangible-Equity is -64.92%. Aspire-Lakewood Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Aspire-Lakewood Holdings (ASBP), the current Return-on-Tangible-Equity is -64.92% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
11GF Score
Get the complete analysis for ASBP
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASBP has been successfully added to your 
